Advertisement

#Kadcyla

Tukysa Regimen Delays Progression of Metastatic Breast Cancer

Adding Tukysa to Kadcyla led to an improvement in progression-free survival, including for patients whose cancer had spread to the brain.

Top 10 Cancer Treatment Highlights of 2019

FDA Approves Enhertu for HER2-Positive Advanced Breast Cancer

60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.

3D rendering of the breast

Tucatinib Fights Breast Cancer That Spreads to the Brain

New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.

Hope Rugo, MD

Margetuximab May Offer New Option for Metastatic Breast Cancer

The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.

Kadcyla

FDA Approves Kadcyla for HER2-Positive Early Breast Cancer

Antibody-drug combination reduced the risk of recurrence after surgery by half compared with Herceptin.

Preventing Breast Cancer Recurrence

Kadcyla reduces the risk of breast cancer recurring and spreading after surgery.

Charles Geyer, Jr., MD

Kadcyla Reduces Breast Cancer Recurrence After Surgery

Experts say Kadcyla should become a new standard of care for adjuvant therapy.

Advertisement